 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Norpace, Rythmodan, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682408 |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Class 1a anti-arrhythmic[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | High |
| Protein binding | 50% to 65% (concentration-dependent) |
| Metabolism | Liver (CYP3A4-mediated) |
| Elimination half-life | 6.7 hours (range 4 to 10 hours) |
| Excretion | Kidney (80%) |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C21H29N3O |
| Molar mass | 339.483 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 94.5 to 95 °C (202.1 to 203.0 °F) |
| |
| |
| (verify) | |
Disopyramide, sold under the brand names Norpace among others, is a medication used to prevent ventricular tachycardia.[1] It is typically only used when other medications are not effective.[1] Use is not recommended for less serious arrhythmias.[1] It is taken by mouth.[1]
Common side effects include dry mouth, constipation, blurry vision, urinary retention, nausea, tiredness, and dizziness.[1] Other side effects may include heart failure, arrhythmias, and low blood sugar.[1] Safety in pregnancy is unclear.[1] It is a class 1a anti-arrhythmic and sodium channel blocker.[1] It has a negative effect on the hearts ability to contract.[1]
Disopyramide was approved for medical use in the United States in 1977.[1] It is available as a generic medication.[2] In the United Kingdom 84 pills of 100 mg costs the NHS about £27 as of 2021.[2] In the United States this amount costs about 55 USD.[3]
References
edit- ^ a b c d e f g h i j k l m "Disopyramide Monograph for Professionals". Drugs.com. Archived from the original on 17 January 2021. Retrieved 26 December 2021.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 110. ISBN 978-0857114105.
- ^ "Disopyramide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 26 December 2021.